InvestorsHub Logo
Followers 49
Posts 3515
Boards Moderated 0
Alias Born 08/24/2005

Re: None

Thursday, 01/23/2020 6:49:39 AM

Thursday, January 23, 2020 6:49:39 AM

Post# of 7369
Revance price target raised to $39 from $34 at Mizuho 06:45 RVNC Mizuho analyst Difei Yang raised her price target for Revance Therapeutics to $39 from $34 after conducting an analysis of Teoxane's family of dermal fillers, specifically looking at market trends in the U.S. and patient reviews of the product in Europe. Based on the analysis, the analyst is incrementally positive on her thesis that the combination of DAXI and RHA has created a "premium, longer-lasting" facial aesthetics portfolio that should benefit from a growing end market. Yang reiterates a Buy rating on Revance shares.

Read more at:
https://thefly.com/landingPageNews.php?id=3021630
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RVNC News